Variants Fok1 and Bsm1 on VDR are associated with the melanoma risk: Evidence from the published epidemiological studies

BMC Genetics

Volumn 16, Issue 1, 2015, Pages

  Hou, Wei ^a   Wan, Xuefeng ^a   Fan, Junwei ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Melanoma; Meta analysis; VDR

Indexed keywords

APA1 PROTEIN; BSM1 PROTEIN; ECORV PROTEIN; FOK1 PROTEIN; TAQ1 PROTEIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; GENE FREQUENCY; GENETIC MODEL; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MELANOMA; META ANALYSIS; SYSTEMATIC REVIEW; GENETIC PREDISPOSITION; GENETICS; METABOLISM; SKIN TUMOR;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; RECEPTORS, CALCITRIOL; SKIN NEOPLASMS;

EID: 84924034572     PISSN: None     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/s12863-015-0163-6     Document Type: Article

References (36)

1. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62(2):357. -368, 375-356, 381-352.
2. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811-23.
3. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011;43(11):1108-13.
4. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6:vi1-7.
5. Pho L, Grossman D, Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol. 2006;18(2):173-9.
6. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122(12):2753-60.
7. Kirkpatrick CS, Lee JA, White E. Melanoma risk by age and socio-economic status. Int J Cancer. 1990;46(1):1-4.
8. Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:162-78.
9. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S-6.
10. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev. 2000;22(2):203-17.
11. Xu Y, He B, Pan Y, Deng Q, Sun H, Li R, et al. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol. 2014;35(5):4153-69.
12. Zinser GM, Sundberg JP, Welsh J. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 2002;23(12):2103-9.
13. Ellison TI, Smith MK, Gilliam AC, MacDonald PN. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J Invest Dermatol. 2008;128(10):2508-17.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
15. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res. 2000;6(2):498-504.
16. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis. 2007;28(2):390-7.
17. Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis. 2007;28(5):1087-93.
18. Santonocito C, Capizzi R, Concolino P, Lavieri MM, Paradisi A, Gentileschi S, et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol. 2007;156(2):277-82.
19. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, et al. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008;122(9):2077-84.
20. Gapska P, Scott RJ, Serrano-Fernandez P, Mirecka A, Rassoud I, Gorski B, et al. Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer Epidemiol. 2009;33(2):103-7.
21. Halsall JA, Osborne JE, Epstein MP, Pringle JH, Hutchinson PE. The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol. 2009;1(1):54-7.
22. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009;45(18):3271-81.
23. Pena-Chilet M, Ibarrola-Villava M, Martin-Gonzalez M, Feito M, Gomez-Fernandez C, Planelles D, et al. rs12512631 on the group specific complement (vitamin D-binding protein GC) implicated in melanoma susceptibility. PLoS One. 2013;8(3):e59607.
24. Zeljic K, Kandolf-Sekulovic L, Supic G, Pejovic J, Novakovic M, Mijuskovic Z, et al. Melanoma risk is associated with vitamin D receptor gene polymorphisms. Melanoma Res. 2014;24(3):273-9.
25. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997;154(Suppl):S57-73.
26. Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T. Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1985;45(11 Pt 1):5426-30.
27. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143-56.
28. Alimirah F, Peng X, Murillo G, Mehta RG. Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells. PLoS One. 2011;6(1):e16024.
29. van Etten E, Verlinden L, Giulietti A, Ramos-Lopez E, Branisteanu DD, Ferreira GB, et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol. 2007;37(2):395-405.
30. Zhang K, Song L. Association between Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk: A Meta-Analysis of 39 Studies. PLoS One. 2014;9(4):e96125.
31. Liu Y, Li C, Chen P, Li X, Li M, Guo H, et al. Polymorphisms in the vitamin D Receptor (VDR) and the risk of ovarian cancer: a meta-analysis. PLoS One. 2013;8(6):e66716.
32. Denzer N, Vogt T, Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol. 2011;3(3):205-10.
33. Chudek J, Karkoszka H, Schmidt-Gayk H, Ritz E, Kokot F. Plasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: are they interrelated? J Nephrol. 2000;13(1):54-8.
34. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res. 1999;14(2):240-7.
35. Schug J, Overton GC. Modeling transcription factor binding sites with Gibbs Sampling and Minimum Description Length encoding. Proc Int Conf Intell Syst Mol Biol. 1997;5:268-71.
36. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today. 2000;21(10):479-83.